445 Marine View Avenue
Suite 320
Del Mar, CA 92014
United States
(858) 925-7000
https://www.lenz-tx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Evert B. Schimmelpennink | President, CEO, Secretary & Director | 886.54k | N/D | 1972 |
Mr. Shawn Olsson | Chief Commercial Officer | 532.13k | N/D | 1983 |
Mr. Marc G. Odrich M.D. | Chief Medical Officer | 576.95k | N/D | 1959 |
Mr. James W. McCollum | Co-Founder & Director | N/D | N/D | 1955 |
Mr. Gerald Horn | Senior Scientific Advisor & Founder | N/D | N/D | N/D |
Mr. Daniel R. Chevallard CPA | Chief Financial Officer | N/D | N/D | 1980 |
Mr. Domenick Porfidia | Vice President of Sales | N/D | N/D | N/D |
Mr. David Murphy | Senior Director of Marketing & Alliance Development | N/D | N/D | N/D |
Mr. Marvin J. Garrett | Senior Vice President of Regulatory & Quality | N/D | N/D | 1951 |
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
La calificación ISS Governance QuickScore de LENZ Therapeutics, Inc. a partir del 1 de mayo de 2024 es 8. Las puntuaciones principales son Auditoría: 9; Junta: 5; Derechos del accionista: 8; Compensación: 9.